AMGN

Amgen Inc. Press Releases

$122.26
*  
0.25
0.2%
Get AMGN Alerts
*Delayed - data as of Jul. 24, 2014  -  Find a broker to begin trading AMGN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    AMGN After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Amgen Announces Webcast of 2014 Second Quarter Financial Results
7/24/2014 4:00:00 PM - PR Newswire

Amgen's Evolocumab is Set to Become the Clinical Gold-Standard Among Statin Add-On Therapies for Dyslipidemia
7/21/2014 10:00:00 AM - PR Newswire

Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
7/17/2014 4:01:00 PM - PR Newswire

Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia
7/1/2014 8:09:00 AM - PR Newswire

Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer
6/16/2014 4:03:00 PM - PR Newswire

Groundbreaking Collaborative Clinical Trial Launched
6/16/2014 9:00:00 AM - PR Newswire

Brodalumab Treatment Improved Clinical Signs And Symptoms In Phase 2 Psoriatic Arthritis Study Published In The New England Journal Of Medicine
6/11/2014 5:00:00 PM - PR Newswire

Amgen Appoints David W. Meline Executive Vice President and Chief Financial Officer
6/9/2014 4:15:00 PM - PR Newswire

Amgen To Present At The Goldman Sachs Global Healthcare Conference
6/6/2014 4:15:00 PM - PR Newswire

Amgen Presents New Data On Talimogene Laherparepvec As Single Agent And Combination Therapy In Metastatic Melanoma At ASCO
6/2/2014 7:44:00 AM - PR Newswire

New Detailed Phase 3 Data Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With A Rare And Serious Genetic Disorder That Causes High Cholesterol
6/1/2014 10:11:00 AM - PR Newswire

Amgen Highlights Phase 2 Results Of Vectibix® (panitumumab) Versus bevacizumab In Combination With FOLFOX In Patients With Wild-Type RAS (KRAS And NRAS) Metastatic Colorectal Cancer
5/31/2014 8:00:00 AM - PR Newswire

Amgen To Present At The Jefferies 2014 Global Healthcare Conference
5/30/2014 4:58:00 PM - PR Newswire

Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma
5/30/2014 8:30:00 AM - PR Newswire

Amgen To Host Post-American Society of Clinical Oncology (ASCO) Summary Webcast
5/29/2014 5:39:00 PM - PR Newswire

RBCC 3D Bioprinting Partner Awarded Prestigious Grant for Microgravity Research
5/29/2014 5:00:00 AM - Business Wire

Amgen and Onyx Data at ASCO 2014 Highlight Oncology Pipeline and Portfolio
5/27/2014 4:01:00 PM - PR Newswire

FDA Approves First-Line Use of Vectibix® (Panitumumab) Plus FOLFOX for Patients with Wild-Type KRAS Metastatic Colorectal Cancer
5/23/2014 5:11:00 PM - PR Newswire

RBCC and n3D Take World’s First Commercially Available 3D Bioprinting System Global
5/22/2014 5:00:00 AM - Business Wire

The New England Journal Of Medicine Publishes Positive Proof-Of-Concept Data For New Asthma Treatment
5/20/2014 4:01:00 PM - PR Newswire

Amgen Announces Voting Results of Annual Meeting of Stockholders
5/15/2014 4:42:00 PM - PR Newswire

Data from Bayer Oncology Portfolio and Pipeline to be Presented at ASCO 2014
5/14/2014 5:00:00 PM - PR Newswire

Journal Of The American Medical Association Publishes Phase 3 LAPLACE-2 Study Showing Evolocumab Significantly Reduced LDL Cholesterol In Patients On Statins Regardless Of Statin Dose
5/13/2014 4:17:00 PM - PR Newswire

Amgen's Breakaway from Cancer® Honors Four California Cancer Survivors During The Ninth Annual Amgen Tour of California
5/12/2014 4:38:00 PM - PR Newswire

Amgen Names Steven K. Galson, Senior Vice President, Global Regulatory Affairs And Safety
5/12/2014 4:03:00 PM - PR Newswire